2026-01-20 - Analysis Report
**Company Overview in One Line**
Regeneron Pharmaceuticals is a multinational biotechnology company that develops and manufactures innovative medical therapies.

**Return Rate Comparison with S&P 500 (VOO)**

| Ticker | Cumulative Return |
|--------|-------------------|
| REGN   | 25.37%            |
| VOO    | 93.30%            |

The divergence between REGN and VOO is -68.00%. This means that S&P 500 (VOO) has exceeded REGN's performance by 68% over the same period.

**Alpha, Beta Analysis**

| Period | CAGR | MDD | Alpha | Beta | Market Cap |
|--------|------|-----|-------|------|------------|
| 2016-2018 | -14.0% | 22.4% | -19.0% | 1.2 | 39.6B      |
| 2017-2019 | -3.0% | 28.6% | -21.0% | 1.0 | 39.8B      |
| 2018-2020 | 2.0% | 28.6% | -19.0% | 0.7 | 51.2B      |
| 2019-2021 | 29.0% | 28.6% | -15.0% | 0.6 | 66.9B      |
| 2020-2022 | 55.0% | 14.4% | 56.0% | 0.6 | 76.5B      |
| 2021-2023 | 46.0% | 14.4% | 45.0% | 0.6 | 93.1B      |
| 2022-2024 | -7.0% | 30.9% | -26.0% | 0.6 | 75.5B      |
| 2023-2025 | -4.0% | 45.4% | -66.0% | 0.6 | 81.8B      |

**Recent Stock Price Fluctuations**

| Metric         | Value    |
|----------------|----------|
| Close          | $733.04  |
| Last Market     | -$1.2%   |
| 5-day SMA      | $751.20  |
| 20-day SMA     | $772.91  |
| 60-day SMA     | $721.13  |

The stock price has shown a slight decline of 0.16% over the last market day.

**RSI, PPO, Market Risk Indicator Analysis**

| Indicator | Value    |
|-----------|----------|
| Market Risk Indicator (MRI) | 0.80     |
| RSI        | 33.66    |
| PPO        | -1.10    |

The Market Risk Indicator is currently at 0.80, indicating a medium-risk investment. The RSI is at 33.66, indicating an oversold condition. The PPO is at -1.10, indicating a sell signal.

**Recent Earnings Analysis**

| Date       | EPS | Revenue |
|------------|-----|---------|
| 2025-10-28 | 14.09 | 3.75 B$ |
| 2025-08-01 | 13.24 | 3.68 B$ |
| 2025-04-29 | 7.58  | 3.03 B$ |
| 2024-10-31 | 12.4 | 3.72 B$ |

**EPS and Revenue Performance**

Earnings per share (EPS) and revenue have shown volatility over the past year, with the EPS increasing from 7.58 to 14.09 and revenue from 3.03 B$ to 3.75 B$.

**Revenue and Profitability Analysis**

| Quarter | Revenue | Profit Margin |
|---------|---------|---------------|
| 2025-09-30 | $3.75B | 86.11%         |
| 2025-06-30 | $3.68B | 85.58%         |
| 2025-03-31 | $3.03B | 84.67%         |
| 2024-12-31 | $3.79B | 85.08%         |
| 2024-09-30 | $3.72B | 86.80%         |

Revenue has shown a slight decline, while profit margin has remained relatively stable.

**Capital and Profitability Analysis**

| Quarter | Equity | ROE |
|---------|--------|-----|
| 2025-09-30 | $30.96B | 4.72% |
| 2025-06-30 | $29.94B | 4.65% |
| 2025-03-31 | $29.39B | 2.75% |
| 2024-12-31 | $29.35B | 3.13% |
| 2024-09-30 | $29.33B | 4.57% |

Equity has shown a slight increase, while return on equity (ROE) has remained relatively stable.

**Analyst Opinions**

Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.69 (~Buy)
- Opinions: 26
- Target Price (avg/high/low): 826.04 / 1057.00 / 630.00

**Recent News & Significant Events**

1. [2026-01-19] Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by ASR Vermogensbeheer N.V. - MarketBeat (news.google.com)
2. [2026-01-14] Is Regeneron (REGN) Offering Value After Recent Share Price Swings? - Yahoo Finance (news.google.com)
3. [2026-01-18] Does Regeneron (REGN) Prioritizing In‑House R&D Over Deals Recast Its Long‑Term Risk‑Reward Profile? - simplywall.st (news.google.com)
4. [2026-01-02] Regeneron Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on January 30, 2026 - Quiver Quantitative (news.google.com)
5. [2026-01-02] REGN Soars 41% in Six Months: Is There More Upside Potential in 2026? - Zacks Investment Research (news.google.com)
6. [2026-01-06] REGN vs. ILMN: Which Stock Should Value Investors Buy Now? - Nasdaq (news.google.com)

**Comprehensive Analysis (Summary of Previous Items)**

The comprehensive analysis of Regeneron Pharmaceuticals (REGN) reveals a company with a stable cash position and solid financial performance. While the stock price has shown a slight decline over the last market day, the cumulative return is still above 25%. The RSI and PPO indicators suggest an oversold condition, indicating a potential buy opportunity. The analyst opinions provide a neutral view with a mean rating of 1.69, indicating a buy recommendation. Overall, REGN presents a stable investment opportunity with a moderate risk level.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.